For a 27‑year‑old female with alcohol use disorder who is taking naltrexone 50 mg daily and gabapentin 300 mg daily but still experiences cravings, should the naltrexone dose be increased?

Do Not Increase Naltrexone Dose Above 50 mg Daily

The standard FDA-approved dose of naltrexone 50 mg daily should not be increased, as higher doses have not been studied in clinical trials for alcohol use disorder and carry increased hepatotoxicity risk. 1 Instead, optimize the current regimen by addressing other factors contributing to persistent cravings.

Why Not Increase Naltrexone?

The FDA label explicitly states that naltrexone 50 mg once daily is the recommended dose for alcohol use disorder, based on placebo-controlled trials demonstrating efficacy at this specific dose for up to 12 weeks 1. Critically, the FDA warns that single doses above 50 mg may carry a higher risk of hepatocellular injury 1. While one small open-label study explored 150 mg daily in 24 patients 2, this lacks the rigor and safety data needed to support routine clinical use, particularly given naltrexone's known hepatotoxicity concerns 3, 4, 5, 4.

Multiple guidelines explicitly caution against naltrexone use in patients with liver disease due to hepatotoxicity risk 4, 6. Although this patient doesn't have documented liver disease, the principle of avoiding unnecessary dose escalation with a potentially hepatotoxic medication remains paramount.

What to Do Instead: Optimize Current Treatment

1. Increase Gabapentin Dose First

Gabapentin 300 mg daily is a subtherapeutic dose for alcohol use disorder. The evidence-based dosing range is 600-1,800 mg/day 6. A landmark study demonstrated that combining naltrexone 50 mg with gabapentin up to 1,200 mg daily significantly improved outcomes compared to naltrexone alone, particularly during the first 6 weeks—specifically reducing heavy drinking days and drinks per drinking day 7.

• Titrate gabapentin to 900-1,200 mg/day divided TID
• Monitor for sedation and mental status changes
• This combination addresses both opioid-mediated reward (naltrexone) and GABA-mediated withdrawal/craving symptoms (gabapentin) 7

2. Consider Adding or Switching to Acamprosate

If cravings persist despite optimized naltrexone-gabapentin combination, add acamprosate 666 mg three times daily 6. Acamprosate has no hepatic metabolism and no hepatotoxicity concerns 6, making it safer than dose-escalating naltrexone. It works via NMDA receptor antagonism, providing a complementary mechanism to naltrexone's opioid antagonism 3.

3. Evaluate for Baclofen in Specific Circumstances

If the patient has any evidence of liver disease or if the above strategies fail, consider switching to baclofen 30-60 mg/day 6. Baclofen is the only medication specifically studied in patients with alcoholic liver disease, showing efficacy in maintaining abstinence 3, 6, 4, 3. However, monitor closely for sedation and mental status changes.

Ensure Comprehensive Treatment Components

Naltrexone efficacy depends heavily on adherence and psychosocial support 1. The FDA label emphasizes that naltrexone "should be considered as only one of many factors determining the success of treatment" and requires "compliance-enhancing techniques" 1. Recent meta-analysis confirms that combining pharmacotherapy with cognitive behavioral therapy or another evidence-based therapy significantly improves outcomes over usual care 8.

Verify the patient is receiving:

• Regular counseling or behavioral therapy (CBT, motivational enhancement therapy)
• Community support (e.g., mutual aid groups)
• Treatment of comorbid psychiatric conditions
• Medication adherence monitoring

Clinical Pearls

• Naltrexone reduces craving through opioid receptor antagonism 9, 10, but this effect plateaus at 50 mg daily
• The combination of naltrexone with gabapentin specifically addresses poor sleep, which is associated with increased drinking 7
• If considering any dose adjustment, assess liver function tests first given naltrexone's hepatotoxicity profile 3, 4, 5
• Extended-release injectable naltrexone 380 mg monthly may improve adherence if compliance is an issue 1, though some patients report late-cycle breakthrough craving 11

Bottom line: Optimize gabapentin dosing to therapeutic levels (900-1,200 mg/day) before considering any other medication changes. This evidence-based approach addresses persistent cravings while avoiding the hepatotoxicity risks of supra-therapeutic naltrexone doses.